HIMS.NYSEHims & Hers Health, INC
DEF: Hims & Hers Health, Inc. Announces 2025 Annual Meeting and Executive Compensation Details
Sentiment:
Proxy Statement
Hims & Hers Health, Inc. has announced its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, along with details on director nominations, executive compensation, and financial performance.
Better than expectedThe company's financial results, including revenue, net income, Adjusted EBITDA, operating cash flow, and free cash flow, all showed significant improvements compared to the previous year.
Summary
- Hims & Hers Health, Inc. will hold its Annual Meeting of Stockholders virtually on June 12, 2025.
- Stockholders of record as of April 14, 2025, are entitled to vote on the election of ten director nominees, ratification of KPMG LLP as the independent accounting firm, and an advisory vote on executive compensation.
- The Board of Directors recommends voting FOR all director nominees, FOR the ratification of KPMG, and FOR the advisory vote on executive compensation.
- Total revenue for FY 2024 was $1.5 billion, a 69% year-over-year increase, and the subscriber base reached 2.2 million, a 45% year-over-year increase.
- Net income for FY 2024 was $126.0 million, compared to a loss of $23.5 million in FY 2023.
- Adjusted EBITDA for FY 2024 was $176.9 million, compared to $49.5 million in FY 2023.
- Operating cash flow for FY 2024 was $251.1 million, compared to $73.5 million in FY 2023.
- Free cash flow for FY 2024 was $198.3 million, compared to $47.0 million in FY 2023.
- The compensation committee increased the annual base salary of Soleil Boughton by 4.55% while other Named Executive Officers' base salaries remained unchanged.
- Named Executive Officers earned 200% of their target annual incentive bonus opportunities due to strong performance in 2024.
- In February 2024, the compensation committee approved equity awards for Named Executive Officers, including Restricted Stock Units (RSUs) and Performance Restricted Stock Units (PRSUs).
Sentiment
Score: 8
Explanation: The document presents a positive outlook with strong financial results and growth metrics, indicating a favorable sentiment.
Positives
- Significant revenue growth of 69% year-over-year, reaching $1.5 billion in FY 2024.
- Substantial increase in the subscriber base, growing by 45% year-over-year to 2.2 million.
- Turnaround to net income of $126.0 million in FY 2024, compared to a net loss in the previous year.
- Strong growth in Adjusted EBITDA, reaching $176.9 million in FY 2024.
- Significant increase in operating cash flow, reaching $251.1 million in FY 2024.
- Substantial growth in free cash flow, reaching $198.3 million in FY 2024.
Negatives
- Gross margin decreased from 82% in 2023 to 79% in 2024.
Risks
- The proxy statement includes forward-looking statements that are subject to risks and uncertainties, which could cause actual results to differ materially from expectations.
- These risks and uncertainties are described in the Risk Factors section of the company's most recently filed Annual Report on Form 10-K.
Future Outlook
The proxy statement includes forward-looking statements regarding expected future financial and business performance, market opportunity, risk oversight, and compensation programs, all of which are subject to change.
Management Comments
- Andrew Dudum, Chief Executive Officer, expressed appreciation for stockholders' continued support and interest in Hims & Hers.
Industry Context
Hims & Hers operates in the telehealth and wellness industry, competing with companies offering digital health solutions and personalized care.
Comparison to Industry Standards
- The document does not provide enough information to make a detailed comparison to industry standards.
- However, the company's growth metrics can be compared to other telehealth companies like Teladoc Health, Amwell, and GoodRx.
- Hims & Hers' revenue growth of 69% year-over-year is a key metric to compare against industry peers.
- Subscriber growth and Adjusted EBITDA margin are also important benchmarks for assessing the company's performance relative to competitors.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Formation of Nominating and Corporate Governance Committee | The Board of Directors recently formed a nominating and corporate governance committee and intends to conduct an annual performance evaluation of this committee. | 2025-04 | Aids the Board with its oversight and to identify individuals qualified to become Board members; to select, or to recommend that the Board select, the director nominees for the next annual meeting of stockholders; to review the effectiveness of our Corporate Governance Guidelines and Code of Conduct, and recommend any proposed changes to the Board; to periodically review the succession planning of our CEO; and to review the annual evaluations of the Board and its committees and use the insights to inform board and committee composition strategy. |
| Stock Ownership Guidelines | In July 2024, the Companys board of directors formally adopted stock ownership guidelines. These guidelines require certain ownership thresholds for the Companys non-employee directors (5x the annual cash retainer for non-employee directors), CEO (5x annual base salary), and other executives (2.5x annual base salary). | 2024-07 | Further support alignment with our stockholders. |
Related Party Transactions
- The spouse of Hims & Hers Chief Operating Officer, Melissa Baird, is the Chief Executive Officer and a stockholder of Woolly Labs, Inc. (d/b/a Vouched), a company that licenses certain commercially available software for identity verification services that is used by Hims & Hers in the ordinary course of its business.
- For the year ended December 31, 2024, Hims & Hers recorded a total of $4.1 million for payments made to Vouched.
Stakeholder Impact
- The company's strong financial performance and growth benefit shareholders through increased value.
- Employees benefit from competitive compensation and benefits programs.
- Customers benefit from access to personalized and affordable health and wellness solutions.
Next Steps
- Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
- The company will hold its Annual Meeting of Stockholders on June 12, 2025.
- The Board of Directors will review and consider the voting results when making future decisions regarding executive compensation programs.
Key Dates
| Date | Description |
|---|---|
| 2025-04-14 | Record date for stockholders entitled to vote at the Annual Meeting |
| 2025-04-25 | Date of proxy statement and notice of Annual Meeting |
| 2025-06-12 | Date of the Annual Meeting of Stockholders |
| 2026 | Date of the next annual meeting of stockholders |
Keywords
executive compensation, annual meeting, proxy statement, financial performance, board of directors, Hims & Hers, stockholders
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.